Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Resistant Solid Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT04261439
What this trial is testing

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

Who this might be right for
In Escalation: All Patients With Solid Tumors and LymphomaIn Expansion: Melanoma, Non-small Cell Lung Cancer
Novartis Pharmaceuticals 60
Early research (Phase 1)Looking for participantsNCT06084481
What this trial is testing

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Who this might be right for
Hepatocellular CarcinomaPancreatic Ductal AdenocarcinomaBiliary Tract Cancers+5 more
AbbVie 325
Testing effectiveness (Phase 2)Study completedNCT04826341
What this trial is testing

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Who this might be right for
HRD CancerSCLCAdvanced Solid Tumors
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT03476681
What this trial is testing

Study of NEO-201 in Solid Tumors Expansion Cohorts

Who this might be right for
Non Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaCervical Cancer+1 more
Precision Biologics, Inc 121
Early research (Phase 1)Ended earlyNCT03878524
What this trial is testing

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Who this might be right for
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAnatomic Stage IV Breast Cancer AJCC v8Anemia+47 more
OHSU Knight Cancer Institute 2
Testing effectiveness (Phase 2)Active Not RecruitingNCT06334432
What this trial is testing

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorHER2-negative Breast CancerMetastatic Castration-resistant Prostate Cancer (mCRPC)+2 more
Nuvation Bio Inc. 466
Early research (Phase 1)Study completedNCT00003555
What this trial is testing

Paclitaxel Plus Chemoprotection With Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors

Who this might be right for
Unspecified Adult Solid Tumor, Protocol Specific
State University of New York - Upstate Medical University 20
Early research (Phase 1)Ended earlyNCT06299761
What this trial is testing

Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications

Who this might be right for
Solid Tumor
Boundless Bio, Inc. 19
Testing effectiveness (Phase 2)WithdrawnNCT07570966
What this trial is testing

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals
Early research (Phase 1)Study completedNCT00316953
What this trial is testing

Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaBlastic Phase Chronic Myelogenous LeukemiaChildhood Chronic Myelogenous Leukemia+5 more
National Cancer Institute (NCI) 48
Testing effectiveness (Phase 2)Looking for participantsNCT07259226
What this trial is testing

Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers

Who this might be right for
Advanced Breast CancerAdvanced Gastric CancerAdvanced Urothelial Cancer+1 more
UNICANCER 400
Early research (Phase 1)Looking for participantsNCT06942104
What this trial is testing

Imaging of Solid Tumors Using 18F-TRX

Who this might be right for
Solid TumorSolid CarcinomaCastration-Resistant Prostate Carcinoma+7 more
Rahul Aggarwal 56
Early research (Phase 1)Study completedNCT01497925
What this trial is testing

Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer

Who this might be right for
Solid TumorsProstate Cancer
Polaris Group 43
Early research (Phase 1)Study completedNCT00589381
What this trial is testing

Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma

Who this might be right for
LymphomaUnspecified Adult Solid Tumor, Protocol Specific
National Institutes of Health Clinical Center (CC) 30
Testing effectiveness (Phase 2)UnknownNCT02266745
What this trial is testing

A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

Who this might be right for
Advanced Solid TumorsCRPCmCRPC+6 more
Promontory Therapeutics Inc. 109
Early research (Phase 1)Study completedNCT02152943
What this trial is testing

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

Who this might be right for
Advanced Malignant Solid NeoplasmEstrogen Receptor PositiveHER2/Neu Positive+10 more
M.D. Anderson Cancer Center 37
Testing effectiveness (Phase 2)Looking for participantsNCT05786924
What this trial is testing

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Who this might be right for
Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more
Institut de Recherches Internationales Servier 554
Testing effectiveness (Phase 2)Looking for participantsNCT05592626
What this trial is testing

A Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsGenital Neoplasm, FemaleUrogenital Neoplasms+11 more
Marengo Therapeutics, Inc. 366
Early research (Phase 1)Study completedNCT03811652
What this trial is testing

A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors

Who this might be right for
Non Small Cell Lung Cancer Squamous (NSCLC-Sq)Head and Neck Squamous Cell Carcinoma (HNSCC)Small Cell Lung Cancer (SCLC)+3 more
MedImmune LLC 8
Early research (Phase 1)Study completedNCT02259114
What this trial is testing

A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)

Who this might be right for
NUT Midline CarcinomaTriple Negative Breast CancerNon-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation+3 more
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 47
Next Page